Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Victoria J. Sinibaldi"'
Autor:
Victoria J. Sinibaldi, Mario A. Eisenberger, Laura A. Sena, Su J. Lim ScM, Emmanuel S. Antonarakis, Mark C. Markowski, John T. Isaacs, Irina Rifkind, Channing J. Paller, Nduku Ngomba, Jun Luo, Caroline F. Pratz, Hao Wang, Michael A. Carducci, Samuel R. Denmeade
Publikováno v:
Eur J Cancer
Background Cyclical, high-dose testosterone administration, termed bipolar androgen therapy (BAT), can induce clinical responses and restore sensitivity to androgen signalling inhibition in patients with previously treated castration-resistant prosta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::874c81e6c44ecebd88c9436d39d0985f
https://doi.org/10.1016/j.ejca.2020.11.043
https://doi.org/10.1016/j.ejca.2020.11.043
Autor:
Victoria J Sinibaldi
Publikováno v:
Clinical Interventions in Aging, Vol Volume 2, Pp 555-560 (2008)
Victoria J SinibaldiSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MA, USAAbstract: Docetaxel is an anti-microtubular agent in the family of the taxanes, now FDA approved as first line chemotherapy for the treatment of hormone
Externí odkaz:
https://doaj.org/article/461e3f974a96437bb4f7c96c98c0d964
Autor:
Benjamin A. Teply, Mario A. Eisenberger, Jun Luo, Michael A. Carducci, Mark C. Markowski, Victoria J. Sinibaldi, Nduku Ngomba, Samuel R. Denmeade, Catherine Handy Marshall, Michael T. Schweizer, Wei Fu, Irina Rifkind, Rana Sullivan, Emmanuel S. Antonarakis, Channing J. Paller, Hao Wang
Publikováno v:
Eur Urol
Background Cyclic high-dose testosterone injections, also known as bipolar androgen therapy (BAT), is a novel treatment strategy for patients with metastatic castration-resistant prostate cancer (mCRPC). BAT has shown clinical activity in prior studi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c3297024f12825b402d9ee3b8b78875
https://europepmc.org/articles/PMC7775877/
https://europepmc.org/articles/PMC7775877/
Autor:
David Sarid, Avivit Peer, Michael A. Carducci, Avishay Sella, Eli Rosenbaum, Raanan Berger, Daniel Keizman, Victoria J. Sinibaldi, Maya Ish-Shalom, Hans J. Hammers, Mario A. Eisenberger, Victoria Neiman, Keren Rouvinov, Wilmosh Mermershtain, Natalie Maimon, Maya Gottfried
Publikováno v:
Clinical Genitourinary Cancer. 14:420-425
Although studies in several cancer types suggest that metformin has antitumor activity, its effect on the outcome of targeted therapies in metastatic renal cell carcinoma (mRCC) is poorly defined. We aimed to analyze the effect of metformin use on th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05fdadd7e3d22c07a7700b2991f1bf03
https://doi.org/10.1016/j.clgc.2016.04.012
https://doi.org/10.1016/j.clgc.2016.04.012
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
The challenges of managing the toxicities associated with the current armamentarium to combat kidney cancer continue to grow. It is therefore paramount for providers to not only have knowledge of the disease, but to also have an understanding of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::655eb1bbf77309e6387fbfa078e6d33a
https://pubmed.ncbi.nlm.nih.gov/30372391
https://pubmed.ncbi.nlm.nih.gov/30372391
Autor:
Hua Ling Tsai, Emmanuel S. Antonarakis, Channing J. Paller, Victoria J. Sinibaldi, Michael A. Carducci, Mario A. Eisenberger, Sammuel R. Denmeade, Rosa Nadal
Publikováno v:
The Prostate. 76:512-520
BACKGROUND Prognostic factors associated with clinical outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with a novel androgen receptor-directed therapies (ARDT) in the second line setting has not been formally
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7eabc5629896ae4ef616e33e7065e976
https://doi.org/10.1002/pros.23141
https://doi.org/10.1002/pros.23141
Autor:
Avivit Peer, Maya Gottfried, Raya Leibowitz-Amit, Victoria J. Sinibaldi, Raanan Berger, Michael A. Carducci, Avishay Sella, Mario A. Eisenberger, Daniel Keizman
Publikováno v:
The Prostate. 74:433-440
BACKGROUND Abiraterone, a potent CYP 17 inhibitor, is standard treatment in docetaxel refractory, metastatic castrate resistant prostate cancer (mCRPC). However, in countries where abiraterone has not been approved yet, or for patients who cannot aff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0919c29d08b1634925e5983bc5ae26cd
https://doi.org/10.1002/pros.22765
https://doi.org/10.1002/pros.22765
Autor:
Danny Y. Song, Samuel R. Denmeade, Theodore L. DeWeese, Michael A. Carducci, Mario A. Eisenberger, Victoria J. Sinibaldi, Jianqing Lin
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 29:670-675
Background This study was designed to evaluate toxicity and preliminary efficacy of 2 cycles of concomitant standard dose/schedule of 153 Sm-lexidronam plus Q 3 weeks schedule escalating doses of docetaxel in metastatic castration-resistant prostate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bee62b938fb035f1e9a74d2ffdeda4a
https://doi.org/10.1016/j.urolonc.2009.10.003
https://doi.org/10.1016/j.urolonc.2009.10.003
Autor:
Samuel R. Denmeade, Marianna Zahurak, Roberto Pili, Daniel Keizman, Charles G. Drake, Mario A. Eisenberger, Emmanuel S. Antonarakis, Michael A. Carducci, Victoria J. Sinibaldi, Susan Hudock
Publikováno v:
Clinical Cancer Research. 16:5269-5276
Purpose: To evaluate the safety and activity of 6 months of treatment with lenalidomide at 5 or 25 mg/d in nonmetastatic biochemically relapsed prostate cancer. Experimental Design: Sixty men with non-castrate, nonmetastatic, biochemically relapsed p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c9d23e22aa5fd520ce9ec6b6733ce1e
https://doi.org/10.1158/1078-0432.ccr-10-1928
https://doi.org/10.1158/1078-0432.ccr-10-1928
Autor:
Rosa, Nadal, Hua-Ling, Tsai, Victoria J, Sinibaldi, Channing J, Paller, Emmanuel S, Antonarakis, Sammuel R, Denmeade, Michael A, Carducci, Mario A, Eisenberger
Publikováno v:
Prostate
BACKGROUND. Prognostic factors associated with clinical outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with a novel androgen receptor-directed therapies (ARDT) in the second line setting has not been formall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fd1faef79b6657c18290d6086ed787ac
https://pubmed.ncbi.nlm.nih.gov/26689606
https://pubmed.ncbi.nlm.nih.gov/26689606